Physician profile
Charles Payne
NPI 1447208913
$5,505.46
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $31.51 · 2021: $1,813 · 2022: $3,020 · 2023: $332 · 2024: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $2,262.37 | 2021-2022 | |
| Axonics, INC. | $1,548.31 | 2020-2023 | Axonics |
| Urovant Sciences INC | $460.87 | 2021-2022 | |
| Astellas Pharma US INC | $196.98 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $189.25 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $171.43 | 2023 | Gemtesa |
| Boston Scientific Corporation | $140.48 | 2022-2024 | Rezum Generator |
| Neotract INC. | $119.45 | 2019-2020 | |
| Tolmar, INC. | $79.02 | 2023 | |
| Rochester Medical Corporation | $71.76 | 2022 | |
| Pfizer INC. | $56.06 | 2022-2023 | |
| Olympus America INC. | $44.73 | 2022-2024 | Itind System |
| Abbvie INC. | $34.86 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.62 | 2022-2024 | |
| Antares Pharma, INC. | $27.99 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $27.34 | 2024 | Nuro |
| C. R. Bard, INC. & Subsidiaries | $22.52 | 2024 | Bard Urinary Drainage Bag |
| Urogen Pharma, INC. | $17.42 | 2023 | Jelmyto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.